MBA BE - Cochlear MD, CEO
| COH Stock | 301.56 3.33 1.12% |
Insider
MBA BE is MD, CEO of Cochlear
| Age | 57 |
| Address | 1 University Avenue, Sydney, NSW, Australia, 2109 |
| Phone | 61 2 9428 6555 |
| Web | https://www.cochlear.com |
Cochlear Management Efficiency
The company has return on total asset (ROA) of 0.1199 % which means that it generated a profit of $0.1199 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1988 %, meaning that it generated $0.1988 on every $100 dollars invested by stockholders. Cochlear's management efficiency ratios could be used to measure how well Cochlear manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Cochlear's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 2.9 B in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 92 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Mrs Schottdorf | Sonic Healthcare | N/A | |
| Stephen Fairy | Sonic Healthcare | N/A | |
| Caroline Raw | Autosports Group | N/A | |
| Nicholas Pagent | Autosports Group | N/A | |
| Jonathan Rutherford | TPG Telecom | N/A | |
| Giovanni Chiarelli | TPG Telecom | N/A | |
| Jen Zemek | TPG Telecom | N/A | |
| Aaron Murray | Autosports Group | N/A | |
| FAICD FRCPA | Sonic Healthcare | 68 | |
| Kieren Cooney | TPG Telecom | N/A | |
| BComm BCom | TPG Telecom | N/A | |
| Iaki Berroeta | TPG Telecom | N/A | |
| Peter Savage | Sonic Healthcare | N/A | |
| Trent Czinner | TPG Telecom | N/A | |
| James Pagent | Autosports Group | N/A | |
| BEc CA | Sonic Healthcare | 56 | |
| David Byrne | Sonic Healthcare | 65 | |
| BCom FACID | Sonic Healthcare | 64 | |
Management Performance
Cochlear Leadership Team
Elected by the shareholders, the Cochlear's board of directors comprises two types of representatives: Cochlear inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cochlear. The board's role is to monitor Cochlear's management team and ensure that shareholders' interests are well served. Cochlear's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cochlear's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Karen ODriscoll, Chief Officer | ||
| Stuart Sayers, Chief Officer | ||
| Dean Phizacklea, Senior Marketing | ||
| Jennifer Hornery, Senior Culture | ||
| Richard MBA, Pres EMEA | ||
| Jan Eng, Chief Officer | ||
| Jennifer Stevenson, VP Brand | ||
| Rob McGrory, Group Secretary | ||
| Kristina Devon, Vice Relations | ||
| Lisa Aubert, Pres America | ||
| MBA BE, MD, CEO | ||
| David Hackshall, Chief Officer | ||
| Anthony Bishop, Pres America | ||
| MComm BE, Senior Chain |
Cochlear Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cochlear a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.2 | ||||
| Return On Asset | 0.12 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | 0.22 % | ||||
| Current Valuation | 19.47 B | ||||
| Shares Outstanding | 65.46 M | ||||
| Shares Owned By Insiders | 0.51 % | ||||
| Shares Owned By Institutions | 48.57 % | ||||
| Price To Book | 10.72 X | ||||
| Price To Sales | 8.97 X |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cochlear Stock Analysis
When running Cochlear's price analysis, check to measure Cochlear's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cochlear is operating at the current time. Most of Cochlear's value examination focuses on studying past and present price action to predict the probability of Cochlear's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cochlear's price. Additionally, you may evaluate how the addition of Cochlear to your portfolios can decrease your overall portfolio volatility.